Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Muthiah Vaduganathan, M.D.

Co-Author

This page shows the publications co-authored by Muthiah Vaduganathan and Ankeet Bhatt.
Connection Strength

9.861
  1. Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots. JAMA. 2021 07 27; 326(4):311-313.
    View in: PubMed
    Score: 0.950
  2. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
    View in: PubMed
    Score: 0.942
  3. Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. J Gen Intern Med. 2021 08; 36(8):2532-2535.
    View in: PubMed
    Score: 0.941
  4. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. Eur J Heart Fail. 2021 07; 23(7):1191-1201.
    View in: PubMed
    Score: 0.931
  5. Discovery and care innovation amidst a pandemic. Eur J Heart Fail. 2020 12; 22(12):2202-2204.
    View in: PubMed
    Score: 0.910
  6. Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients? J Am Coll Cardiol. 2020 11 24; 76(21):2574-2575.
    View in: PubMed
    Score: 0.907
  7. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jul 21; 76(3):280-288.
    View in: PubMed
    Score: 0.876
  8. Reply: Bounded Rationality and Clinical Guidance Documents for Heart Failure. JACC Heart Fail. 2022 Mar; 10(3):213-214.
    View in: PubMed
    Score: 0.247
  9. Personalizing Comprehensive Disease-Modifying Therapy: Obstacles and Opportunities. JACC Heart Fail. 2022 Feb; 10(2):85-88.
    View in: PubMed
    Score: 0.244
  10. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
    View in: PubMed
    Score: 0.243
  11. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC Heart Fail. 2022 Jan; 10(1):1-11.
    View in: PubMed
    Score: 0.242
  12. Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization? J Card Fail. 2021 08; 27(8):910-912.
    View in: PubMed
    Score: 0.238
  13. Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. Am J Cardiol. 2021 10 01; 156:140-142.
    View in: PubMed
    Score: 0.237
  14. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.236
  15. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail. 2021 01; 9(1):65-73.
    View in: PubMed
    Score: 0.228
  16. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. JACC Heart Fail. 2021 01; 9(1):1-12.
    View in: PubMed
    Score: 0.227
  17. Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. Heart Fail Clin. 2020 Oct; 16(4):433-440.
    View in: PubMed
    Score: 0.220
  18. Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. Am J Med. 2020 05; 133(5):525-527.
    View in: PubMed
    Score: 0.214
  19. Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong. Eur J Heart Fail. 2020 02; 22(2):313-314.
    View in: PubMed
    Score: 0.212
  20. Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. Eur J Heart Fail. 2020 01; 22(1):164-167.
    View in: PubMed
    Score: 0.212
  21. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. J Cardiovasc Transl Res. 2022 Mar 15.
    View in: PubMed
    Score: 0.062
  22. Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. Circulation. 2021 07 13; 144(2):177-179.
    View in: PubMed
    Score: 0.059
  23. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.058
  24. Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. Heart Fail Rev. 2021 01; 26(1):11-21.
    View in: PubMed
    Score: 0.057
  25. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 11 17; 76(20):2368-2378.
    View in: PubMed
    Score: 0.057
  26. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J. 2021 02; 232:105-115.
    View in: PubMed
    Score: 0.056
  27. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med. 2020 Sep 09.
    View in: PubMed
    Score: 0.056
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.